NEWARK, Calif. -- BioChain Institute Inc. (“BioChain”), a leader in high-quality processed biosample products and services, and Enable Medicine, a cutting-edge biotechnology company specializing in precision medicine, are pleased to announce their brand-new strategic partnership to advance spatial biology solutions.

The collaboration combines BioChain's extensive experience in biological sample analysis, biospecimens, and advanced molecular diagnostic technologies with Enable Medicine's expertise in generating, managing, and analyzing spatial biology data on its proprietary Enable Cloud Platform. By combining their respective strengths, the two companies aim to revolutionize precision medicine and improve patient outcomes.

Enable Medicine and BioChain are joining hands to provide a comprehensive set of spatial biology tools. The list now includes the Akoya BioSciences proteomics platform, 10x Visium from 10x Genomics, NanoString’s GeoMx, Curio Biosciences’s Slide-seq and Stero-seq from STOmics.

BioChain’s customers now will have access to Enable Medicine’s advanced spatial analysis services, including clustering and neighborhood analysis for 10x Visium.

"We are thrilled to partner with Enable Medicine to advance the field of precision medicine further," says Vidyodhaya Sundaram, Vice President of Business Development at BioChain. "Our combined expertise and resources will allow us to better serve our clients with the most cutting-edge solutions. Via this partnership, we can develop integrated solutions that empower clinicians and researchers to deliver personalized healthcare based on an individual's unique genetic makeup."

BioChain has been at the forefront of providing high-quality products and services, including DNA and RNA extraction kits, PCR reagents, and next-generation sequencing solutions. The company's vast catalog of ethically-sourced tissues has enabled researchers and healthcare professionals worldwide to significantly advance targeted therapies.

Enable Medicine is at the forefront of leveraging protein and genomic data utilizing cutting-edge technologies to develop personalized therapeutics. Their proprietary platform analyzes protein and genomic information to identify specific drivers of diseases, enabling the development of targeted treatments that address the underlying cause of the ailment. Enable Medicine's approach holds immense potential for improving patient outcomes and reducing healthcare costs.

Through this partnership, BioChain and Enable Medicine will collaborate on various initiatives to advance precision medicine. This includes the integration of BioChain's high-quality genomic products and services with Enable Medicine's innovative platform for the development of personalized therapies. By combining their expertise, the two companies aim to accelerate the translation of spatial research into actionable solutions that directly benefit patients.

Sunil Bodapati, CEO of Enable Medicine, commented, "This partnership represents an exciting opportunity to harness the power of genomics and proteomics to deliver targeted therapies for patients. By collaborating with BioChain, we can leverage their extensive experience in genomics research and product development to enhance our precision medicine platform."

Both BioChain and Enable Medicine share a common goal of improving patient care through personalized medicine. This partnership marks a significant step forward in their joint efforts to unlock the full potential of genomics and revolutionize the healthcare industry.

About BioChain®

BioChain, a global leader in biological sample analysis, is a biotechnology company based in Newark, California. BioChain has provided the highest-quality biological research tools and services since 1994. With a focus on spatial biology, developed optimized kits and reagents, prepared DNA, RNA, protein lysates, and tissue sections and arrays, BioChain offers a comprehensive range of products and services, including a diverse collection of ethically sourced biospecimens, advanced molecular diagnostic technologies, and innovative solutions for research and development. Committed to excellence, BioChain's ISO-certified facilities ensure the reliability and integrity of its offerings, making it a trusted partner for scientists, researchers, and clinicians worldwide in their pursuit of breakthrough discoveries and improved healthcare solutions. To learn more about BioChain, visit www.biochain.com

About Enable Medicine

About Enable Medicine: Enable Medicine is a biotechnology company focused on precision medicine solutions. By leveraging multi-modal data and advanced technologies, Enable Medicine develops targeted therapeutics that address the underlying genetic drivers of diseases. Their mission is to improve patient outcomes and revolutionize the way healthcare is delivered. To learn more about Enable Medicine, visit www.enablemedicine.com

Media Contact

Allyson Markey

amarkey@biochain.com

858-442-2167

NGS Webinar

On-Demand Webinar Topic:

Gene-Characterized FFPE Tissues for Validation and Discovery on June 9th

Register for it and we'll send you the recorded talk!

This webinar will be pre-recorded for our international customers. A Youtube link will be emailed to you on June 9th to view the webinar.

Keep an eye out for it!

Please send us questions that you would like to be addressed during the webinar at info@biochain.com

BioChain Introduces New Lines of HPV and Microsatellite instability (MSI) Characterized FFPE Tissue Products

To expand its characterized tissue product line, BioChain proudly introduces HPV Characterized and MSI Characterized FFPE tissue products.

FFPE HPV Characterized

HPV infection has been reported to correlate with several cancer types, especially squamous cell carcinomas originating from head and neck (H&N) as well as cervix tissues. HPVs are classified by genotype, and at least 130 types have been identified by sequencing the gene encoding the major capsid protein L1. High-risk genotypes 16 and 18 are associated with 70% of cervical, and about 80% HPV positive vulval and vaginal carcinoma. Using Diacarta’s QuantiVirus^™ HPV E6/E7 RNA test, BioChain offers HPV-characterized H&N and cervix squamous cell carcinoma tissue sections from various donors as control slides for scientists in this field of study.  Both positive and negative samples are available. Please follow the link below to learn more.

https://www.biochain.com/products/tissue/ffpe-hpv-characterized/

FFPE MSI Characterized

Microsatellite instability (MSI) is the condition of genetic hypermutability (predisposition to mutation) that results from impaired DNA mismatch repair (MMR). MSI is associated with a plethora of cancer types, including colorectal, gastric, endometrium, ovarian, hepatobiliary tract, urinary tract, brain, and skin cancers. However, MSI is most prevalent in association with colon cancer. BioChain has characterized many of these cancer samples using either direct PCR or indirect immunohistochemistry (IHC) with MLH-1, PMS2, MSH-2, and MSH-6 antibodies to give these control samples to the cancer research community. Please follow the link below to learn more.

https://www.biochain.com/products/tissue/ffpe-msi-characterized/

American Society of Human Genetics 2019 Annual Meeting

American Society of Human Genetics (ASHG) 2019 Annual Meeting
Booth# 1608
George R. Brown Convention Center
Houston, TX
October 16-18

Join BioChain Institute Inc. at the ASHG 2019 taking place at the George R. Brown Convention Center in Houston, Texas.

The American Society of Human Genetics Annual Meeting is held each fall in a major U.S. or Canadian city and attracts over 7,000 scientific attendees, plus almost 250 exhibiting companies, which makes it the world’s largest gathering of human genetics professionals. It’s all happening at the George R. Brown Convention Center October 16-18, 2019!

Stop by our booth with any questions or contact us to set up a time to meet while in Houston. Let’s talk about your upcoming genetic testing projects.

Find out what BioChain has to offer in the way of DNA, RNA extracts to the human genetics research community. BioChain also provides kits and instrumentation for nucleic acid purification.

ISHI Annual Meeting 2019

ISHI (International Symposium on Human Identification)
Booth # 115
Palm Springs Convention Center
Palm Springs, CA
September 23-26, 2019

Join BioChain Institute Inc. at the ISHI 2019 taking place at the Palm Springs Convention Center in Palm Springs, California.

The ISHI is the largest annual meeting focusing entirely on DNA forensics. Discover the newest advances in DNA technology from top experts in the field at The 30th International Symposium on Human Identification. It’s all happening at the Palm Springs Convention Center September 23-26, 2019!

Stop by our booth with any questions or contact us to set up a time to meet while in Palm Springs. Let’s talk about your upcoming forensic sample preparation projects.

Find out what BioChain has to offer in the way of DNA, RNA extracts to the forensic research community. BioChain also provides kits and instrumentation for nucleic acid purification.

ASCO Annual Meeting 2019

May 31- June 4, 2019
McCormick Place
Chicago, Illinois

Join BioChain Institute Inc. at the ASCO Annual Meeting 2019 taking place at the McCormick Place in Chicago, Illinois.

The ASCO Annual Meeting is considered the world’s premier oncology conference, organized by the American Society of Clinical Oncology. Every year, the ASCO conference brings together more than 35,000 oncologists from all around the globe, and is attended by all medical, educational and industrial stakeholders involved in the field of oncology worldwide.

Stop by our booth with any questions or contact us to set up a time to meet while in Chicago. Let’s talk about your upcoming life sciences and oncology projects.

Find out what BioChain has to offer in the way of tissues, DNA, RNA, protein extracts to the biopharma and research community (including NGS-characterized tumor sections). BioChain also provides kits and instrumentation for nucleic acid purification that are suitable for liquid biopsy and other purposes, such as Biochain's cfPure® V2 Cell-Free DNA Extraction kits.

BioChain Responds to Epigenomics’ unilateral termination of license contract

March 12, 2019

Newark, CA

BioChain, a US-based company, said today Epigenomics AG of Germany seriously violated the terms of an ongoing licensing contract by publicly announcing on March 6, 2019 the unilateral termination of BioChain’s licensing right of Septin9 marker in China. The termination of the contract by Epigenomics is not legally effective.

BioChain’s CEO, Grace Tian stated that according to the terms of the contract, disputes between the two parties require the parties to go through a mediation and arbitration process.  BioChain filed a request with the contractually specified mediation and arbitration center on March 1, 2019 in accordance with the contract, before Epigenomics unilaterally terminated the contract.

BioChain and its affiliates, as the exclusive licensee of Septin9 marker in China, have diligently worked to expand its market position despite challenging market conditions, including the fact that one relevant patent of Epigenomics was invalidated in China and the news was publicly published in May 2018.

Tian said, “Epigenomics’ termination of the Septin9 contract has incurred damages to BioChain’s reputation and investment and BioChain will take further legal actions to protect its interests”.

Contact:

Company: BioChain Institute Inc. 39600 Eureka Drive, Newark, CA 94560, Tel 510-783-8588, Email info@biochain.com

UCSD Research Supplier Product Show

Join our product specialist Sandy Mavi from BioChain Institute Inc. at the Research Supplier Product Show taking place at the University of California San Diego .

Find out what BioChain’s products have to offer in the way of tissues, DNA and RNA sequencing, PCR and RT-PCR, liquid biopsy kit, gene expression analysis, DNA and RNA purification, protein extraction and purification, and protein expression analysis. BioChain’s One-Stop Services for Next Generation Sequencing, from clinical sample collection, sample preparation, sequencing to bioinformatics analysis, will revolutionize the industry.

Show Details

July 26, 2018
11:00A - 1:30P
University of California, San Diego
Location: Price Center
9500 Gilman Drive
La Jolla, CA

AACR Annual Meeting 2018

April 15-18, 2018
McCormick Place North/South
Chicago, Illinois

Join BioChain Institute Inc. at the AACR Annual Meeting 2018 taking place at the McCormick Place North/South in Chicago, Illinois.

The AACR Annual Meeting highlights the best cancer science and medicine from institutions all over the world. Attendees are invited to stretch their boundaries, form collaborations, attend sessions outside their own areas of expertise, and learn how to apply exciting new concepts, tools, and techniques to their own research.

Stop by our booth with any questions or contact us to set up a time to meet while in Chicago. Let’s talk about your upcoming life sciences and oncology projects.

Find out what BioChain has to offer in the way of tissues, DNA, RNA, protein extracts to the biopharma and research communities (including NGS-characterized tumor sections). BioChain also provides kits and instrumentation for nucleic acid purification that are suitable for liquid biopsy and other purposes.